December 3, 2021 -- Zymeworks has advanced a second Janssen bispecific antibody to clinical development using its Azymetric and Efect therapeutic platforms.
The Azymetric platform enables the transformation of monospecific antibodies into bispecific and multispecific antibodies. This technology can block multiple signaling pathways, recruit immune cells to tumors, enhance receptor clustering and internalization, and increase tumor-specific targeting, the company said.
Additionally, these features reduce toxicities and drug resistance, Zymeworks noted. Azymetric therapeutics are compatible with standard manufacturing processes that deliver high yields and purity, and can reduce drug development costs and timelines.
The Efect platform is a library of antibody Fc modifications engineered to activate or suppress the antibody-mediated immune response. This platform is compatible with Azymetric bispecific antibodies.
Zymeworks will receive a milestone payment according to a 2017 licensing agreement it has with Janssen. Janssen is responsible for all research, development, and commercial activities under the licensing agreement.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
